Cargando…

Amniotic Fluid Cathelicidin in PPROM Pregnancies: From Proteomic Discovery to Assessing Its Potential in Inflammatory Complications Diagnosis

BACKGROUND: Preterm prelabor rupture of membranes (PPROM) complicated by microbial invasion of the amniotic cavity (MIAC) leading to histological chorioamnionitis (HCA) significantly impacts perinatal morbidity. Unfortunately, no well-established tool for identifying PPROM patients threatened by the...

Descripción completa

Detalles Bibliográficos
Autores principales: Tambor, Vojtech, Kacerovsky, Marian, Andrys, Ctirad, Musilova, Ivana, Hornychova, Helena, Pliskova, Lenka, Link, Marek, Stulik, Jiri, Lenco, Juraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399859/
https://www.ncbi.nlm.nih.gov/pubmed/22815956
http://dx.doi.org/10.1371/journal.pone.0041164
_version_ 1782238438468091904
author Tambor, Vojtech
Kacerovsky, Marian
Andrys, Ctirad
Musilova, Ivana
Hornychova, Helena
Pliskova, Lenka
Link, Marek
Stulik, Jiri
Lenco, Juraj
author_facet Tambor, Vojtech
Kacerovsky, Marian
Andrys, Ctirad
Musilova, Ivana
Hornychova, Helena
Pliskova, Lenka
Link, Marek
Stulik, Jiri
Lenco, Juraj
author_sort Tambor, Vojtech
collection PubMed
description BACKGROUND: Preterm prelabor rupture of membranes (PPROM) complicated by microbial invasion of the amniotic cavity (MIAC) leading to histological chorioamnionitis (HCA) significantly impacts perinatal morbidity. Unfortunately, no well-established tool for identifying PPROM patients threatened by these disorders is available. METHODOLOGY/PRINCIPAL FINDINGS: We performed an unbiased exploratory analysis of amniotic fluid proteome changes due to MIAC and HCA. From among the top five proteins that showed the most profound and significant change, we sought to confirm results concerning cathelicidin (P49913, CAMP_HUMAN), since an ELISA kit was readily available for this protein. In our exploratory proteomic study, cathelicidin showed a ∼6-fold higher concentration in PPROM patients with confirmed MIAC and HCA. We verified significantly higher levels of cathelicidin in exploratory samples (women without both MIAC and HCA: median 1.4 ng/ml; women with both conditions confirmed: median 3.6 ng/ml; p = 0.0003). A prospective replication cohort was used for independent validation and for assessment of cathelicidin potential to stratify women with MIAC leading to HCA from women in whom at least one of these conditions was ruled out. We confirmed the association of higher amniotic fluid cathelicidin levels with MIAC leading to HCA (the presence of both MIAC and HCA: median 3.1 ng/ml; other women: median 1.4 ng/ml; p<0.0001). A cathelicidin concentration of 4.0 ng/ml was found to be the best cut-off point for identifying PPROM women with both MIAC and HCA. When tested on the validation cohort, a sensitivity of 48%, a specificity of 90%, a likelihood ratio of 5.0, and an area under receiver-operating characteristic curve of 71% were achieved for identification of women with MIAC leading to HCA. CONCLUSIONS: Our multi-stage study suggests cathelicidin as a candidate marker that should be considered for a panel of amniotic fluid proteins permitting identification of PPROM women with MIAC leading to HCA.
format Online
Article
Text
id pubmed-3399859
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33998592012-07-19 Amniotic Fluid Cathelicidin in PPROM Pregnancies: From Proteomic Discovery to Assessing Its Potential in Inflammatory Complications Diagnosis Tambor, Vojtech Kacerovsky, Marian Andrys, Ctirad Musilova, Ivana Hornychova, Helena Pliskova, Lenka Link, Marek Stulik, Jiri Lenco, Juraj PLoS One Research Article BACKGROUND: Preterm prelabor rupture of membranes (PPROM) complicated by microbial invasion of the amniotic cavity (MIAC) leading to histological chorioamnionitis (HCA) significantly impacts perinatal morbidity. Unfortunately, no well-established tool for identifying PPROM patients threatened by these disorders is available. METHODOLOGY/PRINCIPAL FINDINGS: We performed an unbiased exploratory analysis of amniotic fluid proteome changes due to MIAC and HCA. From among the top five proteins that showed the most profound and significant change, we sought to confirm results concerning cathelicidin (P49913, CAMP_HUMAN), since an ELISA kit was readily available for this protein. In our exploratory proteomic study, cathelicidin showed a ∼6-fold higher concentration in PPROM patients with confirmed MIAC and HCA. We verified significantly higher levels of cathelicidin in exploratory samples (women without both MIAC and HCA: median 1.4 ng/ml; women with both conditions confirmed: median 3.6 ng/ml; p = 0.0003). A prospective replication cohort was used for independent validation and for assessment of cathelicidin potential to stratify women with MIAC leading to HCA from women in whom at least one of these conditions was ruled out. We confirmed the association of higher amniotic fluid cathelicidin levels with MIAC leading to HCA (the presence of both MIAC and HCA: median 3.1 ng/ml; other women: median 1.4 ng/ml; p<0.0001). A cathelicidin concentration of 4.0 ng/ml was found to be the best cut-off point for identifying PPROM women with both MIAC and HCA. When tested on the validation cohort, a sensitivity of 48%, a specificity of 90%, a likelihood ratio of 5.0, and an area under receiver-operating characteristic curve of 71% were achieved for identification of women with MIAC leading to HCA. CONCLUSIONS: Our multi-stage study suggests cathelicidin as a candidate marker that should be considered for a panel of amniotic fluid proteins permitting identification of PPROM women with MIAC leading to HCA. Public Library of Science 2012-07-18 /pmc/articles/PMC3399859/ /pubmed/22815956 http://dx.doi.org/10.1371/journal.pone.0041164 Text en Tambor et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Tambor, Vojtech
Kacerovsky, Marian
Andrys, Ctirad
Musilova, Ivana
Hornychova, Helena
Pliskova, Lenka
Link, Marek
Stulik, Jiri
Lenco, Juraj
Amniotic Fluid Cathelicidin in PPROM Pregnancies: From Proteomic Discovery to Assessing Its Potential in Inflammatory Complications Diagnosis
title Amniotic Fluid Cathelicidin in PPROM Pregnancies: From Proteomic Discovery to Assessing Its Potential in Inflammatory Complications Diagnosis
title_full Amniotic Fluid Cathelicidin in PPROM Pregnancies: From Proteomic Discovery to Assessing Its Potential in Inflammatory Complications Diagnosis
title_fullStr Amniotic Fluid Cathelicidin in PPROM Pregnancies: From Proteomic Discovery to Assessing Its Potential in Inflammatory Complications Diagnosis
title_full_unstemmed Amniotic Fluid Cathelicidin in PPROM Pregnancies: From Proteomic Discovery to Assessing Its Potential in Inflammatory Complications Diagnosis
title_short Amniotic Fluid Cathelicidin in PPROM Pregnancies: From Proteomic Discovery to Assessing Its Potential in Inflammatory Complications Diagnosis
title_sort amniotic fluid cathelicidin in pprom pregnancies: from proteomic discovery to assessing its potential in inflammatory complications diagnosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399859/
https://www.ncbi.nlm.nih.gov/pubmed/22815956
http://dx.doi.org/10.1371/journal.pone.0041164
work_keys_str_mv AT tamborvojtech amnioticfluidcathelicidininpprompregnanciesfromproteomicdiscoverytoassessingitspotentialininflammatorycomplicationsdiagnosis
AT kacerovskymarian amnioticfluidcathelicidininpprompregnanciesfromproteomicdiscoverytoassessingitspotentialininflammatorycomplicationsdiagnosis
AT andrysctirad amnioticfluidcathelicidininpprompregnanciesfromproteomicdiscoverytoassessingitspotentialininflammatorycomplicationsdiagnosis
AT musilovaivana amnioticfluidcathelicidininpprompregnanciesfromproteomicdiscoverytoassessingitspotentialininflammatorycomplicationsdiagnosis
AT hornychovahelena amnioticfluidcathelicidininpprompregnanciesfromproteomicdiscoverytoassessingitspotentialininflammatorycomplicationsdiagnosis
AT pliskovalenka amnioticfluidcathelicidininpprompregnanciesfromproteomicdiscoverytoassessingitspotentialininflammatorycomplicationsdiagnosis
AT linkmarek amnioticfluidcathelicidininpprompregnanciesfromproteomicdiscoverytoassessingitspotentialininflammatorycomplicationsdiagnosis
AT stulikjiri amnioticfluidcathelicidininpprompregnanciesfromproteomicdiscoverytoassessingitspotentialininflammatorycomplicationsdiagnosis
AT lencojuraj amnioticfluidcathelicidininpprompregnanciesfromproteomicdiscoverytoassessingitspotentialininflammatorycomplicationsdiagnosis